A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropat ...
Recurrent IgA Nephropathy
Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids